Hanbury FZE
  • Search
  • Home
  • Products & Services
    • Nutraceutical Ingredients
      • Standardized Phyto Extracts
      • Beverage/Liquid Dietary Supplements
      • GRAS Affirmed Ingredients
      • Minerals for Nutritional Use
      • Phytochemicals for Nutritional Use
      • Multi-enzyme Blends
      • Natural Protein
      • Nutritional Fine Chemicals
      • Phyto Functional Blends
      • Geroceuticals™
      • Prebiotics, Probiotics, Postbiotics and Synbiotics
      • Super Critical Fluid (SCF) Extracts
      • Specialty Fine Chemicals
    • Cosmeceutical Ingredients
      • Natural Actives
      • Peptides
      • Anti-Glycation
      • Dermaceuticals
      • Nutricosmetics
      • Probiotics & Postbiotics
      • Proprietary Cosmeceutical Blends
      • Speciality Chemicals
    • Services
      • Custom Manufacturing
      • Contract Manufacturing
      • Product Specification Sheet
    • Pharma
      • Natural Drugs
      • Chiral Drug Intermediates
  • About Us
    • Our Story
    • Our People
    • Research & Development
    • Manufacturing Facilities
    • Intellectual Properties
  • Newsroom
    • Press Release
    • FAQs
      • BioPerine®
      • Citrin®K
      • Cococin™
      • Curcumin C3 Complex®
      • Curcumin C3 Reduct®
      • ForsLean®
      • GarCitrin®
      • LactoSpore®
      • LeanGard®
  • Contact Us

Home / Sabinsa defends Tetrahydrocurcuminoids patent with legal action

Sabinsa defends Tetrahydrocurcuminoids patent with legal action

Sabinsa defends Tetrahydrocurcuminoids patent with legal action

Sabinsa Corp. has filed lawsuits in the United States District Court, District of New Jersey, against four dietary supplement ingredient companies for making, selling, and/or importing products that infringe upon Sabinsa’s Tetrahydrocurcuminoid Patent covering compositions and methods of using Tetrahydrocurcuminoids in the US. The companies are: Olive Lifesciences Pvt. Ltd. (Bangalore, India), Nachurel Ingredients LLC(North Brunswick, NJ), Chemill Inc. (Bothell, WA), and Aegle Bios Inc. (Edison, NJ). Both Olive and Nachurel were named in a previous suit for infringement on another of Sabinsa’s patents.

The issued U.S. Patent No. 6,653,327, on the compositions and uses of turmeric-derived tetrahydrocurcuminoids is public knowledge, as is Sabinsa’s stated intent to protect the company’s intellectual property.

“We are determined to protect our intellectual property when our patents are infringed upon. These defendants’ customers are also infringing upon Sabinsa’s patents, most likely without their knowledge, so these infringing companies are putting their customer’s businesses at risk,” said Sabinsa founder Muhammed Majeed Ph.D. “We have been very outspoken in calling on industry manufacturers to respect intellectual property; to do otherwise both stifles innovation and does a disservice to those manufacturers who legitimately license intellectual property.”

“Sabinsa’s patent claims compositions and methods of using its tetrahydrocurcuminoid compositions” stated James H. Hulme, Esquire of Arent Fox LLP in Washington, DC, who represents Sabinsa in this matter. “Sabinsa will enforce its patent rights and protect its intellectual property to the fullest extent allowed by law,” he explained.

Sabinsa’s patent covers compositional claims and also several topical and oral applications of Tetrahydrocurcuminoids noted for their high anti-oxidant capacity.

Back
top

HEADQUARTERS

Hanbury FZE


Jebel Ali Free Zone


Warehouse No. RA08AB05


P O Box. 61091


Dubai


United Arab Emirates


+971 4 883 8981

+971 4 883 8978

mail@hanburyfze.ae

CERTIFICATES

Certificate Logos Certificate Logos Certificate LogosCertificate Logos

Global Contacts List

USA India
Utah, USA Japan
Australia Poland
Brasil Korea
Canada South Africa
China Vietnam
Germany  

CONTACT US

    © 2023 Hanbury FZE. All Rights Reserved | Powered by Edkal Technologies | Privacy Policy | Terms of Use | Sitemap | Disclaimer

    • Facebook
    • Twitter
    • LinkedIn
    Disclaimer

    US-FDA: This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

    Usage disclaimer: The information pertaining to any marketing materials by Sabinsa, is for general purposes only. Users are urged to check the validity of patents if any, on any Sabinsa items for their intended use.

    EFSA: This statement has not been evaluated by the EFSA. This product is not intended to diagnose, treat, cure, or prevent any disease.

    Australia: Please note as an ingredient supplier the information contained in this website is for marketers of finished products formulations and is not intended as consumer advice. Marketers should ensure finished products are lawful and comply with the regulations of the countries in which these items are sold. Every care has been taken to ensure the accuracy of the information provided at the time of publication.